Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | completed | Phase 1 | 31 | Fate TherapeuticsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT02592577 |
| MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC |
| completed |
| Phase 1 |
| 28 |
| AdaptimmuneINDUSTRY |
| 4 |
| Dec 9, 2025 |
| clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03542175 | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | completed | Phase 1 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT01089387 | Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction(INSTIN) | completed | Phase 1 / Phase 2 | 18 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03807765 | Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02512172 | A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | completed | Phase 1 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT02950259 | Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) | completed | Phase 1 | 16 | Providence Health & ServicesOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03249142 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer(INeOV) | completed | Phase 1 / Phase 2 | 69 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT03575013 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | completed | Phase 1 | 21 | Yousef ZakhariaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04021043 | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05664971 | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 119 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05767060 | BAT7104 Injection in Patients With Advanced Malignant Tumors. | completed | Phase 1 | 86 | Bio-Thera SolutionsINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT02302469 | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia(RV-WM-0426) | completed | Phase 1 / Phase 2 | 17 | University Hospital, LilleOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT02568553 | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06129422 | Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer | completed | Phase 1 | 10 | Nihon Medi-Physics Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03193190 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | completed | Phase 1 / Phase 2 | 341 | Hoffmann-La RocheINDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02197234 | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | completed | Phase 1 | 52 | AstraZenecaINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT02937571 | High Dose Carfilzomib for Newly Diagnosed Myeloma | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 356 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT04895579 | Lung Cancer With Copanlisib and Durvalumab(LCD) | completed | Phase 1 | 11 | Zhonglin HaoOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT02812667 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Lyudmila Bazhenova, M.D.OTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03738228 | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04647487 | A Study of LY3484356 in Women With Breast Cancer Before Having Surgery(EMBER-2) | completed | Phase 1 | 87 | Eli Lilly and CompanyINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT01489865 | ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 64 | Georgetown UniversityOTHER | 1 | Nov 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 12, 2025source: clinicaltrials